Mayo Clinic researchers report that the expression of two novel genes within the tumors of women with early stage bosom cancer may allow rapport of women who are and are not at risk for early return or cancer-linked death. Results of the study are published in the April 1 issue of Clinical Cancer Research.
“The HOXB13 and IL17BR gene profile was previously discovered as a potential marker of relapse in hormone-receptor positive breast cancer treated with tamoxifen,” says Matthew Goetz, M.D., who co-led the project with James Ingle, M.D. and Fergus Day-bed, Ph.D. “Our unripe study shows that the marker is at most useful for identifying women with a higher risk in the setting of lymph node-negative breast cancer.”
The study, which was conducted by researchers at Mayo Clinic, Harvard Medical School and Arcturus Bioscience, tested whether the expression levels of two genes within women with early stage bust cancer affected the outcomes of women with estrogen receptor-thetical breast cancer. The experimentation team examined tissue from 206 postmenopausal women enrolled in a prospective study conducted by the North Principal Cancer Treatment Collect (NCCTG). They tested the up on of gene expression of HOXB13 and IL17BR from paraffin-embedded tumors and rest that the 2-gene intensity ratio was an independent marker of primeval breast cancer relapse or death in lymph node-negative breast cancer.
“We believe that these findings are clinically important and corroborate the accumulating laboratory matter which suggests that the HOXB13 gene is critically knotty in bust cancer metastases,” says Dr. Goetz. “Further research is needed to decide whether more pushy or additional treatments ordain improve the outcomes of women identified to be at high risk by means of this marker.”
Breast cancer is diagnosed in approximately the same million women each year, and claims the lives of over 40,000 in the United States. More than two-thirds of all breast cancers are hormone positive, and most of these are early stage (lymph node-negative).
—————————-
Article adapted by Medical News Today from card gathering release.
—————————-
Other Mayo Clinic researchers involved with this study (from the Rochester, Minn., and Jacksonville, Fla., sites) included: Vera Suman, Ph.D.; Andrea Nibbe; Daniel Visscher, M.D.; Carol Reynolds, M.D.; Wilma Lingle, Ph.D.; and Edith Perez, M.D. They collaborated with Dennis Sgroi, M.D., from Harvard Medical School; and Tick Erlander, Ph.D., and Xiao-Jun Ma, Ph.D., both from Arcturus Bioscience Inc., Mountain View, Calif.
This research was conducted in part from top to bottom a National Cancer Institute (NCI) SPORE grant — Specialized Programs of Study Goodness. In to boot, it was supported by the NCCTG, Arcturus Bioscience, Inc., and additional grants from the NCI, the Unit of Defense, the Susan G. Komen Breast Cancer Underpinning and the Avon Foundation.
Concerning more information on breast cancer treatment at Mayo Clinic, visit http://www.mayoclinic.org/breast-cancer. To find out more connected with Mayo Clinic’s cancer scrutinization, visit http://cancercenter.mayo.edu/. Information wide NCCTG can be set at http://ncctg.mayo.edu/.
To obtain the latest news releases from Mayo Clinic, go to www.mayoclinic.org/news. MayoClinic.com (http://www.mayoclinic.com/) is ready as a resource to go to your health stories. For more on Mayo Clinic inspection, go to http://www.mayo.edu/.
Get hold of: Elizabeth Zimmermann
newsbureau@mayo.edu
Mayo Clinic